Roche (RHHBY) announced that the phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq and chemotherapy versus pembrolizumab and chemotherapy as an initial treatment for people with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival at its primary analysis with a hazard ratio of 1.27 and overall survival at its first interim analysis with a hazard ratio of 1.33, which was immature. The company intends to halt the study due to reduced efficacy compared to the comparator arm.
Based on the results, the company will evaluate any relevant changes needed to the ongoing tiragolumab programme.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.